You are here

PROFARMA recognizes BIOIBERICA’s commitment to R&D

28 Feb 2012
Bioiberica

Bioiberica is rated “good” and remains within the ‘A’ group, representing companies with significant research activity •The Spanish chemical-pharmaceutical company, which employs 386 workers, has more than 58 R&D projects currently under development.

Barcelona, February 28, 2012. The PROFARMA PLAN committee of the Ministry of Industry has given a "good" rating to Bioiberica, in recognition of its efforts and commitment to R&D. Bioiberica remains within the ‘A’ group, which includes all companies possessing significant research activity and have production plants, or their own R&D centers.

Founded in 1975, Bioiberica is a Spanish chemical-pharmaceutical company, which employs 386 workers. It is active in seven different fields and is specialized in the research, development, production and marketing of bio molecules and new technology for the pharmaceutical, veterinary and agrochemical industries. Mr. Josep Escaich, the company’s CEO, states that “For a company such as ours, maintaining the ‘good’ rating for more than one year, and to remain within the A group, represents a great recognition to our research efforts, with more than 58 R&D projects currently under development”.

The PROFARMA PLAN is a joint project of the following Ministries: Industry, Tourism and Commerce, Healthcare and Social Policies, and Science and Innovation. Its objective is to encourage research and innovation in our country. The classification is done on a year by year basis, and evaluates a number of industrial, economical and R&D activities of the pharmaceutical laboratories of our country.


For further information, please contact:
Alba Soler
Communications Manager, Bioiberica Farma
+34 682 040 776 or +34 93 490 49 08

Aina Mauri
+34 93 217 22 17

Related News

23 Jan 2024
Bioiberica

On a planet where natural resources are limited and there is increasing concern for the environment, the circular economy has emerged as an innovative and sustainable solution.

16 Oct 2023
Bioiberica

We participated in CPHI 2023 in Barcelona, ​​where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.

4 May 2023
Bioiberica

They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs

Bioiberica